| Literature DB >> 32279115 |
Rui Zhang1, Huangqing Ouyang2, Lingli Fu1, Shijie Wang1, Jianglong Han1, Kejie Huang1, Mingfang Jia3, Qibin Song1, Zhenming Fu4.
Abstract
OBJECTIVES: To characterize the chest computed tomography (CT) findings of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) according to clinical severity. We compared the CT features of common cases and severe cases, symptomatic patients and asymptomatic patients, and febrile and afebrile patients.Entities:
Keywords: Chest; Fever; SARS-CoV-2; Tomography
Mesh:
Year: 2020 PMID: 32279115 PMCID: PMC7150608 DOI: 10.1007/s00330-020-06854-1
Source DB: PubMed Journal: Eur Radiol ISSN: 0938-7994 Impact factor: 5.315
Clinical features of patients with SARS-CoV-2 pneumonia by severity type at admission
| Characteristics | All | Common type | Severe type | |
|---|---|---|---|---|
| ( | ( | ( | ||
| Demographics | ||||
| Survival status (alive, %) | 113 (94%) | 90 (100%) | 23 (77%) | < 0.001 |
| Age, mean (SD), years | 45.4 (15.6) | 40.2 (12.9) | 61.2 (12.1) | < 0.001 |
| Sex (male, %) | 43 (36%) | 30 (33%) | 13 (43%) | 0.323 |
| Huanan seafood market exposure history (yes, %) | 3 (3%) | 2 (2%) | 1 (3%) | 1.000 |
| Current smoking (yes, %) | 6 (5%) | 0 | 6 (20%) | < 0.001 |
| Comorbidity3 (yes, %) | ||||
| Any comorbidity | 32 (27%) | 10 (11%) | 22 (73%) | < 0.001 |
| Number, mean (SD) | 0.4 (0.8) | 0.2 (0.6) | 1.2 (0.9) | < 0.001 |
| Diabetes | 7 (6%) | 0 | 7 (23%) | < 0.001 |
| Hypertension | 19 (16%) | 6 (7%) | 13 (43%) | < 0.001 |
| Cardiovascular | 9 (8%) | 4 (4%) | 5 (17%) | 0.035 |
| COPD | 4 (3%) | 1 (1%) | 3 (10%) | 0.048 |
| Malignancy | 7 (6%) | 2 (2%) | 5 (17%) | 0.011 |
| Chronic liver disease | 1 (1%) | 0 | 1 (3%) | 0.250 |
| Other disease | 5 (4%) | 3 (3%) | 2 (7%) | 0.600 |
| Symptoms (yes, %) | ||||
| Any symptom | 104 (87%) | 74 (82%) | 30 (100%) | 0.013 |
| Fever | 81 (68%) | 52 (58%) | 29 (97%) | < 0.001 |
| Cough | 75 (63%) | 49 (54%) | 26 (87%) | 0.002 |
| Dyspnea | 38 (32%) | 11 (12%) | 27 (90%) | < 0.001 |
| Myalgia or fatigue | 57 (48%) | 31 (34%) | 26 (87%) | < 0.001 |
| Headache | 28 (23%) | 10 (11%) | 18 (60%) | < 0.001 |
| Sneeze | 17 (14%) | 1 (1%) | 16 (53%) | < 0.001 |
| Sputum production | 12 (10%) | 0 | 12 (40%) | < 0.001 |
| Pharyngalgia | 16 (16%) | 16 (18%) | 0 | 0.201 |
| Gastrointestinal discomfort | 10 (8%) | 5 (6%) | 5 (17%) | 0.119 |
| Diarrhea | 7 (6%) | 2 (2%) | 5 (17%) | 0.011 |
| No appetite | 3 (3%) | 3 (3%) | 0 | 1.000 |
| Laboratory findings | ||||
| WBC, mean (SD), 109/L | 5.0 (2.2) | 4.7 (1.7) | 5.9 (3.2) | 0.457 |
| N, mean (SD), 109/L | 2.0 (1.7) | 1.6 (1.1) | 3.1 (2.6) | 0.338 |
| L, mean (SD), 109/L | 2.4 (1.8) | 2.5 (1.5) | 2.1 (2.6) | 0.386 |
| LDH, mean (SD), U/L | 235.6 (109.6) | 200.8 (55.9) | 342.8 (157.2) | < 0.001 |
Abbreviation: SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; n, number of cases; SD, standard deviation; WBC, white blood cell; N, neutrophil; L, lymphocyte; LDH, lactate dehydrogenase
1For categorical variables, p values were derived from χ2 test, Fisher’s exact test. For continuous variables, p values were derived from Student t test or analysis of variance (ANOVA)
2p values for the comparison between severe and all common type patients
3Comorbidity included history of diabetes, hypertension, cardiovascular disease, chronic obstructive pulmonary disease (COPD), malignancy, chronic liver disease, and other chronic diseases
CT image interpretations of patients with SARS-CoV-2 pneumonia categorized by severity type
| Chest CT findings | ||||
|---|---|---|---|---|
| All | Common type | Severe type | ||
| ( | ( | ( | ||
| Bilateral | 68 (57%) | 40 (44%) | 28 (93%) | < 0.001 |
| Ground-grass opacities | 107 (89%) | 78 (87%) | 29 (97%) | 0.181 |
| Nodules | 65 (54%) | 53 (59%) | 12 (40%) | 0.072 |
| Linear densities | 75 (63%) | 50 (56%) | 25 (83%) | 0.007 |
| Consolidation | 62 (52%) | 37 (41%) | 25 (83%) | < 0.001 |
| Crazy paving | 30 (25%) | 9 (10%) | 21 (70%) | < 0.001 |
| Bronchiectasis | 14 (12%) | 6 (7%) | 8 (27%) | 0.007 |
| Effusion | 9 (8%) | 0 | 9 (30%) | < 0.001 |
| Lymphadenopathy | 5 (4%) | 1 (1%) | 4 (13%) | 0.134 |
| Air bronchograms | 24 (20%) | 5 (6%) | 19 (63%) | < 0.001 |
| Tree-in-bud sign | 9 (8%) | 4 (4%) | 5 (17%) | 0.042 |
| White lung | 20 (17%) | 0 | 20 (67%) | < 0.001 |
| Lung lobes involved | ||||
| Upper right lobe | 41 (34%) | 16 (18%) | 25 (83%) | < 0.001 |
| Middle right lobe | 50 (42%) | 24 (27%) | 26 (87%) | < 0.001 |
| Lower right lobe | 83 (69%) | 55 (61%) | 28 (93%) | < 0.001 |
| Upper left lobe | 48 (40%) | 22 (24%) | 26 (87%) | < 0.001 |
| Lower left lobe | 79 (66%) | 50 (56%) | 29 (97%) | < 0.001 |
| Number of lobes involved | < 0.001 | |||
| 0 | 6 (5%) | 6 (7%) | 0 | |
| 1 | 43 (36%) | 41 (46%) | 2 (7%) | |
| 2 | 24 (20%) | 22 (24%) | 2 (7%) | |
| 3 | 8 (7%) | 8 (9%) | 0 (0) | |
| 4 | 9 (8%) | 7 (8%) | 2 (7%) | |
| 5 | 30 (25%) | 6 (7%) | 24 (80%) | |
| Predominant distribution | ||||
| Peripheral | 109 (91%) | 79 (88%) | 30 (100%) | 0.064 |
| Central | 39 (33%) | 20 (22%) | 19 (63%) | < 0.001 |
| Predominant patterns | ||||
| Ground-glass opacities | 111 (93%) | 82 (91%) | 29 (97%) | 0.447 |
| Consolidation | 66 (55%) | 41 (46%) | 25 (83%) | < 0.001 |
| Reticulation | 22 (18%) | 4 (4%) | 18 (60%) | < 0.001 |
| Total severity score, mean (SD) | 4.4 (5.3) | 2.0 (1.5) | 11.6 (6.2) | < 0.001 |
| Total level, mean (SD) | 1.6 (1.0) | 1.2 (0.5) | 2.9 (1.0) | < 0.001 |
Abbreviation: SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; n, number of cases
1For categorical variables, p values were derived from χ2 test, Fisher’s exact test. For continuous variables, p values were derived from Student t test or analysis of variance (ANOVA)
2p values for the comparison between severe and all common type patients
Fig. 1(a) Unenhanced axial CT images of an afebrile 37-year-old male doctor with a history of exposure to confirmed SARS-CoV-2 patients. (a1) Patchy ground-glass opacities (GGOs) in the left upper lobe. (a2) Small GGO nodule in the contralateral lower lobe. (A3) Enlarged image of the right lower lobe. (b) Unenhanced axial CT images of an afebrile 28-year-old female with a history of exposure to confirmed SARS-CoV-2 patients presenting with a mild sore throat. (b1) A rounded, ground-glass nodular opacity (GGO) is seen in a subpleural location in the right lower lobe. (b2) Another focal GGO is seen in a subpleural location, in the posterobasal segment of the left lower lobe. (c) Unenhanced axial CT images of a 27-year-old male doctor with a history of exposure to confirmed SARS-CoV-2 patients, initially presenting with fever (39 °C), non-productive cough, dyspnea, and myalgia (c1) who progressed to a severe case requiring oxygen supplementation (c2). (c1) Multifocal, limited GGO is seen in the peripheral zone of both lungs. (c2) Six days later, while oxygen supplementation has been instore, diffuse, bilateral, and ill-defined GGO has developed. Superimposed linear consolidations can be observed, consistent with areas of organizing pneumonia. (d) Unenhanced axial CT images of a 52-year-old male doctor with asthma and exposure to confirmed SARS-CoV-2 patients, initially presenting with fever (39 °C), non-productive cough, dyspnea, and myalgia who rapidly progressed to a severe form requiring mechanical ventilation. (d1) Multifocal, limited GGO in the periphery of both lungs, predominantly affecting left lung. (d2) Two days later, focal GGO has increased in size and density, and new diffuse ill-defined GGO has developed. (d3) After 4 days of mask oxygen supplementation, disease progressed further, with more patchy consolidations and linear densities observed in nearly all lung zones except the anterior part of both lungs. (e) Unenhanced axial CT images of a 57-year-old male with an exposure history initially presenting with fever (38 °C), non-productive cough, dyspnea, myalgia, and headache, being treated for hypertension for 12 years. Diffuse consolidation with air bronchograms is seen in both lungs, with relative sparing of peri-hilar and anterior lung areas, extending from the lung apices to the lung bases. These findings are consistent with a “white lung” appearance
CT image interpretations of common type patients with SARS-CoV-2 pneumonia based on symptoms
| Chest CT findings | |||
|---|---|---|---|
| Common type | |||
| Asymptomatic ( | Symptomatic ( | ||
| Bilateral | 9 (56%) | 31 (42%) | 0.366 |
| Ground-grass opacities | 11 (69%) | 67 (91%) | 0.035 |
| Nodules | 10 (63%) | 43 (58%) | 0.746 |
| Linear densities | 7 (44%) | 43 (58%) | 0.295 |
| Consolidation | 5 (31%) | 32 (43%) | 0.377 |
| Crazy paving | 5 (31%) | 4 (5%) | 0.008 |
| Bronchiectasis | 2 (13%) | 4 (5%) | 0.289 |
| Effusion | 0 | 0 | – |
| Lymphadenopathy | 1 (6%) | 0 | 0.178 |
| Air-bronchogram | 0 | 5 (7%) | 0.581 |
| Tree-in-bud sign | 0 | 4 (5.4%) | 1.000 |
| White lung | 0 | 0 | – |
| Zonal predominance | |||
| Upper | 7 (44%) | 22 (29%) | 0.277 |
| Middle | 3 (19%) | 25 (34%) | 0.373 |
| Lower | 13 (81%) | 57 (77%) | 1.000 |
| Predominant distribution | |||
| Peripheral | 15 (94%) | 64 (86%) | 0.681 |
| Central | 4 (25%) | 16 (22%) | 0.748 |
| Predominant patterns | |||
| Ground-glass opacities | 15 (94%) | 67 (91%) | 1.000 |
| Consolidation | 9 (56%) | 32 (43%) | 0.344 |
| Reticulation | 3 (19%) | 1 (1%) | 0.017 |
| Total severity score, mean (SD) | 1.9 (0.9) | 2.0 (1.6) | 0.565 |
Abbreviation: SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; n, number of cases
1For categorical variables, p values were derived from χ2 test, Fisher’s exact test. For continuous variables, p values were derived from Student t test or analysis of variance (ANOVA)
CT image interpretations of common type patients with SARS-CoV-2 pneumonia based on having fever or not
| Pneumonia chest CT findings | |||
|---|---|---|---|
| Common type | |||
| Afebrile ( | Febrile ( | ||
| Bilateral | 18 (47%) | 22 (42%) | 0.776 |
| Ground-grass opacities | 29 (76%) | 49 (94%) | 0.014 |
| Nodules | 23 (61%) | 30 (58%) | 0.787 |
| Linear densities | 19 (50%) | 31 (60%) | 0.365 |
| Consolidation | 16 (42%) | 21 (40%) | 0.870 |
| Crazy paving | 6 (16%) | 3 (6%) | 0.118 |
| Bronchiectasis | 3 (8%) | 3 (6%) | 0.694 |
| Effusion | 0 | 0 | – |
| Lymphadenopathy | 1 (3%) | 0 | 0.422 |
| Air-bronchogram | 0 | 5 (10%) | 0.071 |
| Tree-in-bud sign | 2 (5%) | 2 (4%) | 1.000 |
| White lung | 0 | 0 | – |
| Zonal predominance | |||
| Upper | 11 (29%) | 18 (35%) | 0.570 |
| Middle | 12 (32%) | 16 (31%) | 0.935 |
| Lower | 28 (74%) | 42 (81%) | 0.425 |
| Predominant distribution | |||
| Peripheral | 34 (89%) | 45 (87%) | 0.754 |
| Central | 9 (24%) | 11 (21%) | 0.776 |
| Predominant patterns | |||
| Ground-glass opacities | 33 (87%) | 49 (94%) | 0.275 |
| Consolidation | 19 (50%) | 22 (42%) | 0.470 |
| Reticulation | 3 (8%) | 1 (2%) | 0.307 |
| Total severity score, mean (SD) | 1.8 (1.2) | 2.1 (1.6) | 0.767 |
Abbreviation: SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; n, number of cases
1For categorical variables, p values were derived from χ2 test, Fisher’s exact test. For continuous variables, p values were derived from Student t test or analysis of variance (ANOVA)
Final multivariate analysis of the association for selected characteristics with the severity of SARS-CoV-2 pneumonia
| Characteristics | OR (95% CI)1 | |||
|---|---|---|---|---|
| Common | Severe | |||
| Baseline2 | ||||
| Age mean (SD) | 40.2 (12.9) | 61.2 (12.1) | 0.003 | 1.1 (1.0–1.1) |
| Comorbidity mean (SD) | 0.2 (0.6) | 1.2 (0.9) | 0.138 | 1.8 (0.8–3.8) |
| LDH > 250 U/L | 18 (20%) | 21 (70%) | 0.116 | 2.5 (0.8–7.8) |
| Symptoms3 | ||||
| Dyspnea | 11 (12%) | 27 (90%) | < 0.001 | 31.1 (6.5–148.8) |
| Headache | 10 (11%) | 18 (60%) | 0.102 | 3.9 (0.8–19.6) |
| CT findings4 | ||||
| Crazy paving | 9 (10%) | 21 (70%) | 0.002 | 15.3 (2.6–89.5) |
| Air bronchogram | 5 (6%) | 19 (63%) | < 0.001 | 41.8 (5.9–298.4) |
Abbreviation: SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; n, number of cases; LDH, lactate dehydrogenase
1Derived from multivariate analysis of logistic regression models
2Retained in this model were age, comorbidity (number of comorbidities) and LDH > 250 U/L.
3Retained in this model were age, comorbidity (number of comorbidities), LDH > 250 U/L, dyspnea (yes) and headache (yes)
4Retained in this model were age, comorbidity (number of comorbidities), LDH > 250 U/L, crazy paving (yes) and air bronchogram (yes)